Equi-Phar ButePaste 20 GramThis page contains information on Equi-Phar ButePaste 20 Gram for veterinary use.
The information provided typically includes the following:
- Equi-Phar ButePaste 20 Gram Indications
- Warnings and cautions for Equi-Phar ButePaste 20 Gram
- Direction and dosage information for Equi-Phar ButePaste 20 Gram
Equi-Phar ButePaste 20 GramThis treatment applies to the following species:
For Veterinary Use Only
ANADA 200-266, Approved by the FDA.
Phenylbutazone Paste is a synthetic, non-hormonal, anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound’s anti-inflammatory properties.
Chemically, Phenylbutazone Paste is 4-butyl-1, 2-diphenyl-3, 5-pyrazolidinedione. It is a pyrazolone derivative, entirely unrelated to the steroid hormones.
Equi-Phar ButePaste 20 Gram Indications
For the relief of inflammatory conditions associated with the musculoskeletal system in horses.
Use with caution in patients who have a history of drug allergy.
WARNING: Not for use in horses intended for food.
PrecautionsStop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man; fatal reactions, although rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of two weeks thereafter. Any significant fall in the total white blood cell count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter-measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.
ADMINISTRATION AND DOSAGE: Orally - 1 to 2 g of phenylbutazone per 500 lb of body weight daily. Do not exceed 4 g daily.
Guidelines to Successful Therapy: Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response. Response to Phenylbutazone Paste therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after five days, re-evaluate diagnosis and therapeutic approach. When administering Phenylbutazone Paste, the oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose. Many chronic conditions will respond to Phenylbutazone Paste therapy, but discontinuance of treatment may result in recurrence of symptoms.
StorageStore at 15°-30°C (59°-86°F).
How SuppliedSyringes containing 20 g of Phenylbutazone.
KEEP OUT OF REACH OF CHILDREN
Equi-Phar ButePaste 20 Gram Caution
Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
Each syringe contains 20 g phenylbutazone.
Each 3 mL marking on the plunger contains Phenylbutazone: 1 g.
Manufactured by: Med-Pharmex, Inc., Pomona, CA 91767-1861
Manufactured for: VEDCO, St. Joseph, MO 64507 USA
NAC No.: 10942872
5503 CORPORATE DR., ST. JOSEPH, MO, 64507
|Every effort has been made to ensure the accuracy of the Equi-Phar ButePaste 20 Gram information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2018 North American Compendiums. Updated: 2018-04-26